USPTO Issues Memoranda Reshaping PTAB Discretionary Denial Approa

If you’ve ever filed (or defended) an inter partes review (IPR) or post-grant review (PGR), you already know the PTAB can feel a bit like airport security:
you might have a perfectly valid ticket (a strong unpatentability case), but you can still get pulled aside for “additional screening” (discretionary denial).
In 2025, the USPTO issued a set of memoranda and process updates that do more than tweak the linethey redesigned the whole checkpoint.

The result? Discretionary denial arguments are no longer just a few pages of “Fintiv factor bingo” folded into the prelim response.
Instead, they’ve become a separate, Director-centered process with new timing rules, new briefing expectations, and new (sometimes surprising) factors
that can decide the fate of a petition before the PTAB ever reaches the merits.

Not legal advice; just practical, real-world-informed analysis for practitioners and stakeholders.

PTAB Discretionary Denial: The Concept in Plain English

“Discretionary denial” is the PTAB’s ability to say: “Even if you’ve met the basic statutory threshold to institute, we’re not going to institute
this challenge right now (or at all) because other circumstances make it inefficient, duplicative, unfair, or misaligned with PTAB resources.”
The legal hook typically traces to the institution statutes (35 U.S.C. §§ 314(a) and 324(a)) and has been shaped by precedential PTAB decisions.

Why it matters more than it sounds

Institution denials are often decisive. If a petition is denied, the challenger doesn’t get the PTAB’s fast track to an expert tribunal and (potentially)
an estoppel-triggering final written decision. In parallel litigation, that can change settlement leverage, motion practice, and even trial strategy.
That’s why discretionary denial doctrineespecially when tied to parallel district court or ITC proceedingshas become a headline issue in patent disputes.

A Quick Timeline: The Memos That Moved the Goalposts

The USPTO’s recent approach is best understood as a sequence: a 2022 guidance memo that created clearer “safe harbors,” a 2025 rescission that removed those
guardrails, and a 2025 workload-management memo that rebuilt the discretionary denial process into a bifurcated, Director-led system.

What the Feb. 2025 Rescission Really Did (and Didn’t Do)

The February 28, 2025 rescission didn’t erase Fintivit effectively put Fintiv back in the driver’s seat as the default framework for parallel-proceeding
discretionary denial. But the important nuance is this: the rescission also signaled that discretionary denial would return to being a more
holistic balancing exercise, rather than an analysis with a few “automatic overrides.”

Three key practical changes

• ITC proceedings are back on the table. Under the 2022 guidance, ITC parallel proceedings were treated as a reason not to deny;
  the 2025 guidance indicates the Board may apply Fintiv logic to ITC target dates as a practical matter.
• Sotera-style stipulations still help, but they’re not dispositive. A strong stipulation can reduce duplication concerns,
  but it’s now part of the totality-of-circumstances analysis rather than an on/off switch.
• “Compelling merits” is relevant, not a trump card. Strong merits can weigh against denial, but the PTAB signaled that merits alone
  won’t necessarily override other factors.

Translation: the rescission didn’t create a single new rule; it removed the old shortcuts and pushed everyone back into a more fact-intensive balancing world.
If you miss one factual dominolike how close the district court is to trial, or how much investment has already happenedyou can lose the discretionary fight
even with a respectable merits case.

The March 26, 2025 Workload Memo: The Big Structural Overhaul

The March 26, 2025 memorandum is the real tectonic shift. It introduced a bifurcated institution process:
(1) discretionary considerations get decided first by the Director (with consultation from at least three PTAB judges),
and (2) only if discretionary denial is not applied does the petition proceed to a merits panel for the “normal” institution decision.

Why the USPTO did this

The memo frames the change as workload managementmaintaining PTAB capacity for AIA trials while also meeting statutory duties like ex parte appeals.
Practically, this means discretionary denial can function as a resource-allocation filter: some petitions may never reach a full merits institution analysis
if the Director determines they’re inefficient, duplicative, or otherwise not the best use of PTAB bandwidth.

Separate briefing: the new procedural reality

Under the interim process, discretionary denial is no longer something you “sneak in” as a side dish. It has its own briefing lane, with its own timing.
Early on, that lane was word-limited; later 2025 updates moved it to page limits (20 pages for requests due on or after September 1, 2025).

Another major practice note: the USPTO’s process guidance emphasizes that parties should not present discretionary arguments in the petition or the Patent Owner
Preliminary Response (POPR). The petition and POPR are for merits and other non-discretionary statutory issues; discretionary denial lives in the separate brief.
In other words: stop trying to smuggle Fintiv into the merits suitcaseit’s going through a different scanner now.

Beyond Fintiv: The New-ish Factors Parties Ignore at Their Own Risk

Fintiv remains the best-known discretionary denial framework, especially for parallel litigation. But the 2025 workload memo and related guidance underscore
that discretionary denial isn’t just about trial dates. The Director may consider a wider set of circumstances, including:

• Prior adjudications: whether PTAB or another forum has already adjudicated validity/patentability of the same claims.
• Changes in law: new judicial precedent or legal shifts that might affect patentability since issuance.
• Strength of the challenge: merits strength can matter, but now as one factor in a discretionary balancing test.
• Reliance on expert testimony: how much the petition depends on experts (which can impact efficiency and complexity).
• Settled expectations: how long claims have been in force and what the parties reasonably relied on over time.
• Public-interest considerations: compelling economic, public health, or national security interests.
• PTAB workload realities: ability to meet ex parte appeal pendency goals and AIA deadlines.

Two of these have become especially “real” in early decisions and commentary: settled expectations and petitioner delay/awareness.
In plain terms, the USPTO is signaling that waiting years to file an IPRespecially when the challenger knew about the patentcan become a discretionary
strike against institution, even before you get to the substance.

Strategy for Petitioners: How to Reduce Discretionary Denial Risk

Petitioners don’t control everything (like a district court’s calendar), but they control enough to move the needleespecially now that discretionary denial
is decided in a dedicated lane with Director-level attention.

1) File early like you mean it

The “settled expectations” and “delay/awareness” theme is a neon sign: if you knew about the patent years ago, and you only filed once litigation got hot,
expect the patent owner to argue you’re gaming the system. If the business reality requires waiting, build a record explaining why the challenge was not
reasonably brought earlier (e.g., product launch timing, newly asserted claims, newly discovered prior art, or a concrete change in litigation posture).

2) Treat stipulations as precision tools, not slogans

A Sotera-style stipulation can still reduce overlap with district court/ITC issues, but it’s not self-executing. Make it:
(a) timely (before institution), (b) clear in scope, and (c) aligned with what the patent owner will argue about duplication.
The USPTO’s guidance also hints that stipulations may be less meaningful when other invalidity theories or “system art” remain in play elsewhere.

3) Plan for a two-stage institution fight

Under bifurcation, you may need to win twice: first on discretion, then on merits. That changes how teams allocate effort.
A common best practice is to build a “discretion record” earlytrial schedule evidence, stay posture, overlap analysis, and a clean narrative
for why PTAB review improves efficiency rather than duplicating effort.

4) Don’t waste briefing space repeating your petition

The USPTO’s process guidance effectively warns petitioners not to treat the discretionary opposition as “bonus merits pages.”
Use the opposition to explain how merits strength matters to the discretionary balance (without copy-pasting the petition),
and focus heavily on efficiency, timing, and duplication.

Strategy for Patent Owners: Turning Discretion into a Front-End Win

Patent owners now have a clearer procedural doorway to argue discretionary denial early, directly, and with the expectation that the Director will issue a
discretionary decision when a brief is filed. That’s a major strategic shift: the discretionary denial brief can be a true gatekeeper.

1) Build a credibility-first trial schedule story

If your parallel case is moving fast, make it easy for the decision-maker to see it. Provide:
scheduling orders, claim construction timelines, trial dates, ITC target dates, and concrete markers of investment (fact discovery status, expert reports,
dispositive motion deadlines). You’re telling a simple story: “The court/ITC will resolve this before the PTAB would, so instituting would duplicate work.”

2) Emphasize overlap and duplication (with specifics)

Overlap arguments work best when they are surgical: map petition grounds to litigation invalidity contentions, explain shared witnesses/expert topics,
and highlight how institution would force parallel validity fights on the same claims at the same time.

3) Use “delay” and “settled expectations” thoughtfully

These factors can be powerful, but they’re not a substitute for good facts. If the patent is older and the petitioner has long been aware of it,
document that awareness with real record anchors (citations, prosecution history references, product timelines, prior interactions).
The goal is to show the petition isn’t a good-faith, timely request for reviewit’s a late-stage tactical detour.

Specific Examples: What the New Framework Looks Like in Real Disputes

Example A: Fast-moving district court case (high Fintiv risk)

Imagine a medical device dispute in a district known for relatively quick trial settings. The court sets a trial date that lands several months before the
PTAB’s projected final written decision deadline. The patent owner has already exchanged infringement/invalidity contentions, completed claim construction,
and scheduled expert discovery. Under the current approach, the patent owner’s discretionary denial brief can argue:
(1) heavy investment, (2) close-to-trial posture, and (3) duplicationmaking the case a prime candidate for discretionary denial.

Example B: Older patent + long-known exposure (settled expectations risk)

Consider an electronics company that cited the patent family years ago during its own prosecution or internal diligence, then files an IPR only after being
sued. Under the workload memo’s “settled expectations” framing, the patent owner may argue: “This challenger knew about these claims for a decade and did nothing
until litigation pressure arrived.” Even if the petition is technically strong, the discretionary stage becomes a real risk area because the Director can view
the timing as unfair or inefficient system use.

Example C: ITC investigation with an aggressive target date

If an ITC target date for final determination is earlier than the PTAB’s final decision deadline, the PTAB has indicated it may be more likely to deny
institutionbecause, as a practical matter, the ITC’s outcome can shape the real-world enforceability landscape even without strict preclusion.
That makes ITC-heavy disputes especially sensitive to tight timing and well-documented procedural milestones.

Where This Is Headed: “Interim” Doesn’t Always Mean “Short-Lived”

The USPTO has used memoranda and web-guidance to implement these changes quickly, and it has also explored formal rulemaking in this area.
Notably, a proposed PTAB rules package addressing discretionary denial briefing and related issues was later withdrawn in October 2025,
leaving the current approach heavily dependent on guidance documents, precedential decisions, and Director-led processes.

That combination creates a reality practitioners should plan for:
the doctrine may keep evolving through additional guidance and Director decisions, with less of the “locked-in” predictability that a final
rule might have provided. If you’re building a PTAB strategy playbook, make sure it’s a living documentnot a dusty binder from last quarter.

Conclusion: The New PTAB Discretionary Denial Era Is a Two-Round Fight

The headline change isn’t just that the USPTO rescinded one memo and issued another. It’s that discretionary denial has become a structured, Director-centered
front-end gate with expanded considerations and clearer process mechanics. Fintiv still matters, but it’s now joined by workload management realities and
additional discretionary factors that reward early action, clean narratives, and disciplined briefing.

For petitioners, the winning formula is increasingly: file earlier, reduce overlap, document efficiency, and treat discretion as a first-class battlenot an
afterthought. For patent owners, the opportunity is just as real: a strong discretionary denial record can end the proceeding before merits even enter the room.

Experiences in Practice: What Teams Commonly See Under the “New” Discretionary Denial Approach (Extra Section)

Even without a single “one-size-fits-all” rule, the post-memo environment tends to create a predictable set of human experiences for the people doing the work:
counsel, in-house teams, and business leaders trying to answer a deceptively simple question“Are we going to get instituted?” Here are patterns that show up again
and again when discretionary denial moves from policy memo to day-to-day reality.

First: teams feel the process split in their bones. Before bifurcation, discretionary denial arguments often lived in the shadow of the merits.
Now, many practitioners plan the case like a two-round boxing match. Round one is not “Are the claims invalid?” It’s “Should the PTAB spend time on this at all?”
That mindset shift changes staffing, budgeting, and even client communicationsbecause you can have a technically elegant petition and still lose the discretionary round
if the timing or duplication story is ugly.

Second: the “schedule obsession” becomes very real. Teams start tracking district court and ITC milestones with the intensity of sports fans checking
playoff brackets. A single rescheduled trial date, a delayed Markman hearing, or a newly granted stay motion can swing the discretionary narrative.
In practice, that means litigators and PTAB counsel coordinate earlier and more oftensometimes weeklyso the discretionary briefing reflects the most current posture.
It also means teams learn (the hard way) that conclusory statements like “trial is unlikely to happen then” are less persuasive than concrete docket evidence.

Third: “delay” arguments feel different when they’re framed as fairness and expectations rather than just timing. Practitioners routinely see patent owners
dig into old prosecution histories, past product launches, prior licensing talks, and even unrelated patent filings to show that a petitioner knew about a patent long ago.
On the petitioner side, teams respond by building a chronology that explains why an earlier PTAB challenge wasn’t practical or justifiedsometimes pointing to newly asserted
claims, newly discovered prior art, a new competitor product, or a litigation event that changed the stakes. The experience is less about citing cases and more about telling a
believable timeline story that doesn’t look like gamesmanship.

Fourth: briefing discipline becomes a competitive advantage. In many matters, the teams that do best treat the discretionary brief as a focused advocacy product:
crisp facts, clear charts, minimal throat-clearing, and a tight tie between evidence and the exact discretion factors being invoked. Teams that struggle often do the opposite:
they reargue the petition, paste in long merits blocks, or throw every factor at the wall to see what sticks. Under a Director-centered process, that scattershot approach can
backfirebecause it makes the decision-maker do extra work to find the actual point.

Finally: the emotional experience is… sharper. Institution risk has always existed, but discretionary denial can feel especially high-stakes because it is
tied to policy, efficiency, and tribunal resourcesnot just the perceived strength of the patent. Many stakeholders describe it as “being graded on a rubric you didn’t write.”
The practical coping mechanism is preparation: treat discretion as a front-end priority, gather evidence early, and write as if the discretionary decision is the first and most
important decision in the casebecause sometimes it is.